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Background: Cardiac resynchronization therapy plays important role in treatment of heart
failure patients with low left ventricular ejection fraction. However, a signiﬁcant number of
patients do not improve after implantation. Optimization of atrioventricular and inter-
ventricular delay could improve clinical status of these patients.
Objectives: The purpose of this study was to compare optimization of atrioventricular (AV)
and interventricular (VV) delays with aortic velocity-time integral (VTI) and with maximal
value of the ﬁrst derivative of a left ventricular pressure signal (LVdP/dtmax).
Methods: Fifteen non-responders were optimized with aortic VTI method and QuickOpt.
After 3 months the follow up echocardiography and clinical evaluation were done. Ten
non-responders were optimized with LVdP/dtmax and QuickOpt. After 3 month follow up
echocardiography and clinical evaluation were done.
Results: In the ﬁrst group of patients (age 74.3 years (65.3, 84.3), 83.4% male, etiology 66%
ischemic heart disease, NYHA class before optimization III 66.7%, III-IV 33.3%, LVEF 23.0%
(15.0; 32.0)), no correlation between AV and VV delays setting obtained from aortic VTI and
QuickOpt was found. Optimization generated shorter QRS complex. After 3 months of
follow up, there was no change in echo parameters or NYHA class. In the second group of
patients (age 76.7 years (66.6, 82.4), 90% male, etiology 60% ischemic heart disease, NYHA
class before optimization III 50%, III-IV 50%, LVEF 29.5% (10.0; 35.0)), no correlation between
AV and VV delays setting obtained from LVdP/dtmax and QuickOpt was found. Optimization
in this group of patients also generated shorter QRS complex. After 3 months, increase in
LVEF was observed, but other echo parameters and NYHA class remained unchanged.
Conclusion: Using aortic VTI guided optimization in CRT devices did not bring any proﬁt for
non-responder patients. Echocardiography parameters and NYHA status did not changed
in 3 months follow up. Using invasive LVdP/dtmax leads to a change in left ventricular
ejection fraction, but NYHA class remains unchanged.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Cardiac resynchronization therapy (CRT) plays an important
role in the treatment of heart failure patients with a low left
ventricular ejection fraction (LVEF). However, a signiﬁcant
number of patients do not improve after implantation. The
percentage of non-responders varies in clinical trials between
16% [1] and 42% [2]. This wide range of clinical outcomes is
interpreted by several ways. The patient selection is very
important–different clinical trials address different patient
population. Moreover, there is a lack of consensus of the
deﬁnition of non-responders [3] itself. Several different strate-
gies could be taken into account to deﬁne response of CRT
therapy. Outcome data are based on mortality and cardiac
morbidity (mainly hospitalization for heart failure). Measure-
ments of remodeling reﬂect parameters of LVEF and left
ventricular (LV) volumes–predominantly LV end-systolic and
end-diastolic volumes. Clinical measurements like New York
Heart Association (NYHA) Functional Classiﬁcation of symp-
toms could be somehow subjective. More objective may be
6min walking test and peak VO2. Questionnaire like Quality of
life score or The Minnesota Living with Heart Failure ques-
tionnaire and others reﬂect good pragmatic evaluation of
patients with heart failure. Some of the authors described
endpoints with subjective inﬂuence as soft endpoints [4] in
contrast with objective hard endpoints—as mortality. Large
clinical trials of CRT often use composite endpoints. This
approach increases the number of observed events, however
it could decreases clinical relevance. Which patients do beneﬁt
from CRT the most? Recent data from MADIT-CRT [5] identiﬁed
seven factors that predict better outcome: female, non-ischemic
disease, left bundle branch block, wide QRS complex (4150ms),
prior hospitalization for heart failure, LV end-diastolic volume
≥125mL/m2, and left atrial volumeo40mL/m2. In other words:
patient with interventricular dyssynchrony with wide QRS
complex, with no large regions of scar tissue, who have already
had symptoms of heart failure would more likely proﬁt from
CRT. Several suggestions have been proposed to turn the non-
responders to responders: (1) checking device status: stimula-
tion threshold, checking of lead position and pacing vectors,
checking percentage of CRT stimulation, optimization of atrio-
ventricular (AV) and interventricular (VV) delays, (2) optimiza-
tion of medical treatment, (3) treatment of arrhythmias: atrial
ﬁbrillation and premature ventricular contractions may reduce
CRT stimulation, (4) treatment of underlying cardiac (especially
ischemia and valvular problems) and non-cardiac disorders
(anemia, thyroid disorders and others). Optimization of AV
and VV delays should be integral part of treating non-
responders. Unfortunately, there is no consensus about meth-
odology used for optimization of timing cycles. Several non-
invasive methods [6] are used: most of them are echo based and
iterative (as measurement of aortic VTI, mitral VTI, Ritter
method and others). Integrated algorithms in devices are based
on intracardiac electrogram measurements and they compute
optimal AV delay (Smart AV [6]) or both optimal AV and VV
delays (QuickOpt [7]). Other methods as using photoelectric
pletismography or thoracic impedance are not so widely used.
Gold standard in measurement of cardiac output is invasive
measurement using LVdP/dtmax.2. Methods
2.1. Echocardiography optimization: aortic VTI
Method of measurement of continuous-wave Doppler aortic
velocity–time integral (aortic VTI) is well known and estab-
lished [8]. The algorithm for assessment of optimal AV delay
in dual chamber devices was described by Mehta et al. [9].
A prospective randomized clinical trial comparing optimal AV
delay determined by aortic VTI versus 120 ms ﬁxed was
published by Sawhney et al. [10]. Brieﬂy, in the ﬁrst place
we measured aortic VTI in expiration in sinus rhythm with
AV delays (sensed AV delay) varying from 220 ms to 100 ms in
10 ms steps (with simultaneous CRT stimulation) to deter-
mine maximal aortic VTI. The same measurements were
done during atrial pacing with the rate 10 beats per minute
exceeding intrinsic heart rhythm (paced AV delay). As opti-
mal AV delay we considered the AV delay with the highest
aortic VTI. In the next step, we changed VV delays (from LV
ﬁrst 60 to +60) at the optimal AV delay to assess optimal
VV delay.
2.2. LVdP/dtmax
This index was originally described in the work of Kass et al. [11].
The principle behind is the measurement one of isovolu-
metric phase indexes—maximal value of the ﬁrst derivative
of a left ventricular pressure signal (LVdP/dtmax) with differ-
ent setting of AV and VV delay. The technique of invasive
optimization using assessment of LVdP/dtmax was described
by Auricchio et al. [12] and modiﬁed by van Gelder et al. [13].
Briskly, LVdP/dtmax is measured with sensor tipped pressure
guide wire with thickness 0.014 in. called PressureWire Cer-
tus™ (St. Jude Medical), which is led through a 4Fr multi-
purpose catheter to left ventricle through radial or femoral
artery. The calculation of LVdP/dtmax was performed with
PhysioMon software. LV pressure and LVdP/dtmax were
recorded 1 respiratory cycle, calculated electronically for
every beat, and averaged over the period of measurement.
After The AV/VV delay change, a waiting period of 30 s was
used to achieve hemodynamic stabilization. LVdP/dtmax was
measured during intrinsic rhythm and during atrial pacing at
a rate 10 beats per minute (bpm) exceeding the intrinsic rate.
The optimal AV interval was determined during simulta-
neous biventricular stimulation (VV interval 0 ms) at AV
intervals starting from 230 ms (or 10 ms below spontaneous
PQ interval) to 100 msec in 10 msec step as an interval with
the maximum LVdP/dtmax With this AV interval, the VV
interval was changed from 60 ms (LV ﬁrst) to 60 ms (RV ﬁrst)
in 20-ms intervals. The CRT systems in this study (St. Jude
Medical) use the VV timing, in which the ﬁrst ventricular
stimulus is delivered at the programmed AV interval and the
second stimulus is delayed with the programmed VV interval.
2.3. QuickOpt™ (St. Jude medical, cardiac rhythm
management division, Sylmar, CA, USA)
This IEGM-based AV/PV delay method is based on work of
Baker et al. [7]. It is a practical method based on the clinical
Table 1 – Basic characteristic of all CRT patients (N¼395).
Valuesa
Age 68 (49; 79)
Gender
Female 61 (15.44%)
Male 334 (84.56%)
Symptoms
Heart failure 291 (73,67%)
Stokes–Adams syndrome 60 (15.19%)
Cardiac arrest 31 (7.85)
Bradycardia 13 (3.29%)
Etiology
DCM 187 (47.34%)
IHD 3VD 85 (21,52%)
IHD 2VD 54 (13.67%)
IHD 1VD 33 (8.35%)
IHD coronary anatomy unknown 36 (9.11)
NYHA class
I 1 (0.25%)
II 63 (15.95%)
III 209 (52.91%)
IV 1 (0.25%)
Unknown 121 (30.63%)
LVEF 25 (15; 35)
Rhythm
Sinus 351 (88.86%)
Atrial ﬁbrillation 44 (11.14%)
Device
CRT-P 111 (28.1%)
CRT-D 284 (71.90%)
Death
Yes 45 (11.39%)
No 350 (88.61%)
Abbreviations: DCM: dilated cardiomyopathy, IHD: ischemic heart
disease, 3VD: 3 vessel disease, 2 VD: 2 vessel disease, 1 VD: 1 vessel
disease, NYHA: New York Heart Association, CRT-P: pacemaker
with cardiac resynchronization therapy, CRT-D: implantable car-
dioverter-deﬁbrillator with cardiac resynchronization therapy.
a Absolute and relative frequencies for categorical variables;
median supplemented by 5th and 95th percentile range for
continuous variables.
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programmer algorithm measures the width of the atrial
intrinsic depolarization and adds an offset factor of 30 or
60 ms (depends on the time of intrinsic depolarization), so
ventricular pacing is delivered when atrial electrical activa-
tion and mechanical contraction are completed. AV delay is
calculated as the amount of the PV delay and the pacing
latency (50 ms). The IEGM-based VV delay algorithm is based
on the hypothesis that during the optimal VV delay, two
paced depolarization wave fronts activated at the RV and LV
leads will meet near the interventricular septum. VV delay
algorithm has two components: the conduction delay (δ) and
the correction term (ε). δ is the difference between the time of
peak intrinsic activation on the LV lead (RLV) and the RV lead
(RRV) [δ¼RLVRRV]. The correction term ε is the difference in
the interventricular conduction delay (IVCD) between two
ventricular paced propagation waveform time delays. The
correction term equation is ε¼ IVCD  LRIVCD RL. The IEGM
optimal VV delay (VV)¼0.5(δ+ε) and if VV40, the LV is
activated ﬁrst and if VVo0, the RV is activated ﬁrst. The
outcome from clinical trial FREEDOM [14], which pointed out
the question of efﬁcacy of QuickOpt algorithm, was not
published yet.
2.4. Responder versus non-responder
There is a variety of possibilities how to deﬁne the response
of CRT therapy and the agreement between different studies
is poor [15]. In our study, we use composition of change in
LVEF and NYHA class. Patients who have developed increas-
ing in LVEF more than 5% and those, who had improvement
of NYHA class during follow up were classiﬁed as responders
[16]. Patients who have developed drop in LVEF more than 5%
and have decreased the NYHA class during the follow up
were classiﬁed as non-responders. All between were classi-
ﬁed as unchanged.
2.5. Study protocol
From all patients with sinus rhythm who underwent CRT
implantations in between 01.01.2007 and 31.08.2012 we
selected those, who had at least one echocardiography
examinations before implantation and at least one after
implantation at our department. Patients, who were classiﬁed
as non-responders and agreed with further investigation, were
scheduled for the optimization. Prior to the optimization, all
patients underwent echocardiographic study together with the
follow-up (to conﬁrm, that LV electrode is pacing correctly, to
assess percentage of CRT pacing, to convince that optimal
medical therapy is used).
To determine optimal AV and VV delays three methods
were used: aortic VTI measurement, QuickOpt algorithm and
LVdP/dtmax assessment. The patients were divided into two
groups.
In a ﬁrst group of patients two methods were used for
comparison of optimal AV and VV delay—aortic VTI based
and QuickOpt based. In the former method we optimized AV
and VV interval according to aortic VTI. We started to search
the best AV delay using the greatest aortic VTI value. With
optimized AV delay we continued with determination of thebest VV delay. This was performed during spontaneous sinus
rhythm (sensed AV delay) and atrial stimulation of 10 beats
per minute above sinus rhythm (paced AV delay). In the latter
method we used QuickOpt to set the optimal AV and VV
delay. In the case of different results, aortic VTI based
parameters which were taken into account only. ECG was
recorded without CRT stimulation and with optimized AV
and VV delays. Next follow up including standard echocar-
diographic measurements was done in 3 months after
optimization.
In the second group of patients the best AV delay was
measured using LVdP/dtmax. The optimal VV delay was also
measured by LVdP/dtmax using the same protocol described
already. All patients underwent the QuickOpt assessment
similarly to the ﬁrst group. In case of different results, LVdP/
dtmax based parameters were taken into account only. ECG
Table 2 – CRT patients with chocardiography follow-ups
(N¼144).
Valuesa
Age 70 (60; 79)
Gender
Female 26 (18%)
Male 118 (82%)
Etiology
DCM 56 (38.9%)
IHD 1VD 13 (9.0%)
IHD 2VD 26 (18.1%)
IHD 3VD 20 (13.9%)
IHD coronary anatomy unknown 29 (20.1%)
Device
CRT-D 78 (54.2%)
CRT-P 66 (45.8%)
Place of RA electrode
Appendage 98 (68.1%)
Not speciﬁed 46 (31.9%)
Place of RV electrode
Apex 65 (45.1%)
Septum 57 (39.6%)
Not speciﬁed 22 (15.3%)
Place of LV electrode
Lateral 77 (53.5%)
Postero-lateral 30 (20.8%)
anterior 12 (8.3%)
Not speciﬁed 25 (17.4%)
NYHA class at implantation
I 0 (0.0%)
II 28 (19.4%)
III 112 (77.8%)
IV 4 (2.8%)
Atrial rhythm at implantation
Sinus 127 (88.2%)
Atrial ﬁbrillation 17 (11.8%)
Atrial rhythm at follow-upb
Sinus 100 (69.4%)
Atrial ﬁbrillation 44 (30.6%)
Echo before implantation
LVEF 26.2 (15;35)
LVEDV 221.2 (113.2;334.8)
LVESV 162.1 (68.9;278.4)
SV 57.1 (29.6;82.5)
LVEDD 63.93 (50;78.8)
LVESD 54.1 (36.2;72.5)
Echo after implantationb
LVEF 34.4 (15;58.2)
LVEDV 203.9 (98.4;317.2)
LVESV 140.4 (51.3;239.3)
SV 62.7 (26.2;105.5)
LVEDD 62.48 (50;78.6)
LVESD 51.9 (33.2;71.0)
Responsec
Responders 62 (43.1%)
Unchanged 53 (36.8%)
Non-responders 29 (20.1%)
Abbreviations: DCM: dilated cardiomyopathy, IHD: ischemic heart
disease, 3VD: 3 vessel disease, 2 VD: 2 vessel disease, 1 VD: 1 vessel
disease, NYHA: New York Heart Association, CRT-P: pacemaker
with cardiac resynchronization therapy, CRT-D: implantable car-
dioverter-deﬁbrillator with cardiac resynchronization therapy; RA:
right atrium, RV: right ventricle, LV: left venticle, LVEF: left
ventricular ejection fraction, LVEDV: left ventricular end-diastolic
volume, LVESV: left ventricular end-systolic volume, SV: stroke
volume, LVEDD: left ventricular end diastolic diameter, LVESD: left
ventricular end systolic diameter.
a Absolute and relative frequencies for categorical variables;
median supplemented by 5th and 95th percentile range for
continuous variables.
b Follow-up: 7687415 days.
c Response: change in NYHA and LVEF.
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AV and VV delays. Next follow up including standard echo-
cardiographic measurements was done 3 months after
optimization.2.6. Statistics
Standard descriptive statistics were used in the analysis—
absolute and relative frequencies for categorical variables;
median supplemented by 5th and 95th percentile range for
continuous variables. Paired comparison of patients before
and after optimization was computed using McNemar test for
categorical variables and Wilcoxon paired test for continuous
variables. Comparison of patients with different types of
optimization was done using Fisher exact test for categorical
variables and Mann–Whitney U test for continuous variables.2.7. Study population
In the period from 1.1.2007 to 31.12.2011, there were 494
implantations of CRT (both CRT-D and CRT-P) systems
carried out in our department. The total number of patients
with complete medical history data was 395. 84.56% of
patients were male. The average age was 68 (49; 79), average
LVEF was 25 (15; 35)%. The underlying cardiac disease leading
to CRT implantation was ischemic heart disease (52.66%) and
dilated cardiomyopathy (47.34%). Basic characteristics of all
CRT patients are shown in Table 1. During the follow-up of
1189 days (7556 days, minimum 109, maximum 2153 days)
45 deaths (11.3%) were observed.
Only 144 patients were included in the further evaluation
as they had at least two echocardiographic assessments in
our department (see Table 2.). The average age was 70 (60; 79),
82.0% of patients were male and 59.7% of patients had
ischemic heart disease as underlying disease. CRT-D was
implanted in 54.2% of patients. Majority of our patients were
in NYHA class III at time of implantation (77.8%). LVEF was
changed from 26.2 at time of implantation to 34.4 during
follow-up. Sinus rhythm at time of implantation was present
in majority of patients (88.2%). Sinus rhythm remained in
69.4% patients during follow-up. All patients received optimal
medical therapy (furosemide, spironolactone, beta blockers,
ACE-inhibitors or AR blockers), and regular follow up in the
outpatient clinic. From this group of patients 29 of them were
classiﬁed as non-responders (decrease in LVEF and NYHA
class), all with sinus rhythm. 25 of them agreed with
Table 3 – Basic characteristic of non-respondersa.
Echo opt. (N¼15) Invasive opt. (N¼10)
Age 74 (65; 84) 76 (67; 82)
Gender
Female 4 (26.67%) 1 (10%)
Male 11 (73.33%) 9 (90%)
Etiology
DCM 5 (33.33%) 4 (40%)
IHD 3VD 4 (26.67%) 3 (30%)
IHD 2VD 3 (20.00%) 1 (10%)
IHD coronary anatomy unknown 3 (20.00%) 2 (20%)
NYHA class
III 10 (66.67%) 5 (50%)
III–IV 5 (33.33%) 5 (50%)
LVEF 23 (15; 32) 29.5 (10.0; 35.0)
Device
CRT-P 7 (46.67%) 5 (50%)
CRT-D 8 (53.33%) 5 (50%)
Place of RA electrode
Appendage 14 (93.33%) 9 (90%)
Not speciﬁed 1 (6.67%) 1 (10%)
Place of RV electrode
Apex 8 (53.33%) 6 (60%)
Septum 6 (40.0%) 3 (30%)
Not speciﬁed 1 (6.67%) 1 (10%)
Place of LV electrode
Lateral 8 (53.33%) 6 (60%)
Postero-lateral 4 (26.67%) 1 (10%)
Anterior 2 (13.33%) 2 (20%)
Not speciﬁed 1 (6.67%) 1 (10%)
Abbreviations: opt. Optimization, DCM: dilated cardiomyopathy, IHD: ischemic heart disease, 3VD: 3 vessel disease, 2 VD: 2 vessel disease, 1
VD: 1 vessel disease, RA: right atrium, RV: right ventricle, LV: left venticle, NYHA: New York Heart Association, CRT-P: pacemaker with cardiac
resynchronization therapy, CRT-D: implantable cardioverter-deﬁbrillator with cardiac resynchronization therapy.
a Absolute and relative frequencies for categorical variables; median supplemented by 5th and 95th percentile range for continuous variables.
Table 4 – Comparison of AV and VV delays-echo optimization (N¼15)a.
Aortic VTI Quickopt Paired comparison
(N¼11)-pb
Spearman correlation
(N¼11)
p
Paced AV delay 150.0 (110.0; 180.0) 150.0 (110.0; 170.0) 0.365 0.457 0.158
Sensed AV delay 110.0 (90.0; 140.0) 110.0 (90.0; 130.0) 0.206 0.537 0.089
VV delay 0.389 0.328 0.325
LV 40 1 (6.7%) –
LV 35 – 1 (6.7%)
LV 30 1 (6.7%) –
LV 20 7 (46.7%) 4 (26.7%)
LV 10 1 (6.7%) 2 (13.3%)
LV¼RV 2 (13.3%) 3 (20.0%)
RV 10 2 (13.3%) –
RV 20 1 (6.7%) 1 (6.7%)
Undetermined – 4 (26.7%)
Abbreviations: aortic VTI: velocite time integral; AV: atrioventricular, VV: interventricular, LV: left ventricle ﬁrst, RV: righ ventricle ﬁrst.
a Absolute and relative frequencies for categorical variables; median supplemented by 5th and 95th percentile range for continuous variables.
b Paired comparison using Wilcoxon paired test for continuous variables (VV delay also recoded into quantitative variable).
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Table 5 – Comparison of parameters before and after echo-optimization (N¼15)a.
Before After Difference pb
Aortic VTI 11.7 (9.0; 18.8) 15.4 (11.7; 22.8) 3.4 (1.0; 6.9) 0.001
QRS width 170.0 (160.0; 190.0) 170.0 (140.0; 180.0) 10.0 (20.0; 10.0) 0.013
LVEF 23.0 (15.0; 32.0) 25.0 (10.0; 54.0) 8.0 (19.0; 22.0) 0.140
LVEDV 210.0 (124.0; 285.0) 220.0 (82.0; 339.0) 10.0 (122.0; 78.0) 0.798
LVESV 163.0 (76.0; 232.0) 158.0 (52.0; 286.0) 6.0 (92.0; 65.0) 0.820
SV 48.0 (30.0; 76.0) 53.0 (18.0; 89.0) 18.0 (30.0; 41.0) 0.249
LVEDD 67.0 (58.0; 74.0) 66.0 (41.0; 79.0) 3.0 (18.0; 12.0) 0.691
LVESD 58.5 (48.0; 69.0) 57.0 (44.0; 71.0) 2.0 (18.0; 11.0) 0.826
NYHA class 0.687
II 0 (0%) 3 (20.0%)
III 10 (66.7%) 5 (33.3%)
III–IV 5 (33.3%) 7 (46.7%)
Abbreviations: aortic VTI: aortic velocite time integral, LVEF: left ventricular ejection fraction, LVEDV: left ventricular end-diastolic volume,
LVESV: left ventricular end-systolic volume, SV: roke volume, LVEDD: left ventricular end diastolic diameter, LVESD: left ventricular end
systolic diameter, NYHA (New York Heart Association).
a Absolute and relative frequencies for categorical variables; median supplemented by 5th and 95th percentile range for continuous variables.
b Paired comparison using McNemar test for categorical variables and Wilcoxon paired test for continuous variables.
Table 6 – Comparison of AV and VV delays-LVdP/dt optimization (N¼10)a.
LV dP/dtmax Quickopt Paired comparison (N¼8)-pb Spearman correlation (N¼8) p
Paced AV delay 155.0 (130.0; 190.0) 150.0 (140.0; 160.0) 0.286 0.325 0.432
Sensed AV delay 125.0 (100.0; 150.0) 110.0 (100.0; 120.0) 0.089 0.086 0.840
VV delay 0.483 0.255 0.542
LV 40 2 (20.0%) 1 (10.0%)
LV 35 – 1 (10.0%)
LV 20 5 (50.0%) 3 (30.0%)
LV 10 – 1 (10.0%)
LV¼RV 1 (10.0%) 2 (20.0%)
RV 10 – –
RV 20 2 (20.0%) –
Unknown – 2 (20.0%)
Abbreviations: LV dP/dtmax: maximal value of the ﬁrst derivative of a left ventricular pressure signal, AV (atrioventricular), VV (interven-
tricular), LV (left ventricle ﬁrst), RV (right ventricle ﬁrst).
a Absolute and relative frequencies for categorical variables; median supplemented by 5th and 95th percentile range for continuous variables.
b Paired comparison using Wilcoxon paired test for continuous variables (VV delay also recoded into quantitative variable).
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went further optimization, is shown in Table 3.3. Results
In the ﬁrst group of patients we used echocardiography
measurements of aortic VTI for optimization of CRT device.
Fifteen non-responders (age 74.3 years (65.3, 84.3), 83,4%
male, etiology 66% ischemic heart disease, NYHA class before
optimization III 66.7%, III–IV 33.3%, LVEF 23.0 (15.0; 32.0)) were
optimized with aortic VTI method and QuickOpt. The opti-
mized paced and sensed AV delays are listed in Table 4.
There was no correlation between AV and VV delays setting
obtained from aortic VTI and QuickOpt. The optimization
generated shorter QRS complex. After 3 months of the follow
up, there was no change in echo parameters or NYHA class
(see Table 5).The patients in second group were optimized invasively
using LVdP/dtmax, measurements. Ten non-responders (age
76.4 years (66.6, 82.4), 90% male, etiology 60% ischemic heart
disease, NYHA class before optimization III 50%, III–IV 50%,
LVEF 29.5 (10.0; 35.0)) were optimized with LVdP/dtmax and
QuickOpt. Optimized paced and sensed AV delays are listed
in Table 6. There was no correlation between AV and VV
delays setting obtained from LVdP/dtmax and QuickOpt. The
optimization in this group of patients generated shorter QRS.
complex. After 3 month, increase of LVEF was observed, but
others echo parameters and NYHA class remained unchanged
(see Table 7).4. Discussion
Our study did not conﬁrm any impact of CRT optimization
with using aortic VTI in the group of non-responders. The
Table 7 – Comparison of parameters before and after dP/dt optimization (N¼10)a.
Before After Difference pb
LV dP/dtmax 633 (483;1005) 854 (675;1072) 199 (36; 316) 0.005
QRS width 170.0 (160.0; 190.0) 160.0 (150.0; 180.0) 10.0 (30.0; 10.0) 0.035
LVEF 29.5 (10.0; 35.0) 37.0 (21.0; 49.0) 10.5 (14.0; 20.0) 0.041
LVEDV 174.5 (119.0; 334.0) 177.5 (103.0; 306.0) 18.0 (116.0; 77.0) 0.285
LVESV 194.0 (111.0; 277.0) 77.0 (74.0; 80.0) – –
SV 58.5 (40.0; 82.0) 57.0 (39.0; 89.0) 3.0 (31.0; 49.0) 0.593
LVEDD 64.5 (50.0; 80.0) 62.5 (50.0; 75.0) 2.0 (18.0; 13.0) 0.483
LVESD 57.0 (41.0; 73.0) 47.0 (39.0; 68.0) 2.0 (18.0; 19.0) 0.212
NYHA class 0.625
II 2 (20.0%)
III 5 (50.0%) 5 (50.0%)
III–IV 5 (50.0%) 3 (30.0%)
Abbreviations: LV dP/dtmax: maximal value of the ﬁrst derivative of a left ventricular pressure signal, LVEF: left ventricular ejection fraction,
LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic volume, SV: stroke volume, LVEDD: left ventricular end
diastolic diameter, LVESD: left ventricular end systolic diameter, NYHA: New York Heart Association.
a Absolute and relative frequencies for categorical variables; median supplemented by 5th and 95th percentile range for continuous variables.
b Paired comparison using McNemar test for categorical variables and Wilcoxon paired test for continuous variables.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 2 9 3 – e 3 0 0 e299optimizing had no impact on change in NYHA class or
changed in echocardiographic parameters during 3 month
of follow-up. Kerlan et al. [17] demonstrated acute improve-
ment of systolic function using aortic VTI guided optimiza-
tion in comparison to the mitral inﬂow method. Hardt et al.
[18] found improvement of 6 min walking test and decreasing
in BNP level 40 days after AV delay optimization, surprisingly
no improvement in quality of life was found. Unfortunately,
RHYTHM II ICD study [19] failed to show beneﬁt of VV
optimization using aortic VTI (however, each patient has
AV optimization as a standard part of CRT therapy). Also in
study of Rao et al. [20] there was no beneﬁt in group of CRT
with VV optimization compared to group with simultaneous
CRT pacing.
Correlation in settings obtained from aortic VTI measure-
ments and QuickOpt in our study is poor. This ﬁndings
contrast with work of Baker et al. [7]. In his study was the
correlation strong and linear. The possible explanation is
large variations in AV and VV intervals result in only small
changes in aortic VTI.
We observed that optimizing CRT devices according to
LVdP/dtmax results in change of LVEF, however no effect on
patients NYHA class was documented. This contrasts with
literature–optimization with LVdP/dtmax is something like
“gold” standard. We suggest that possible explanation is
small number of patients in our study and short follow-up.
There is also no correlation between AV delay settings
obtained from LVdP/dtmax measurements and QuickOpt. Like-
wise, work of Van Gelder et al. [21] showed no correlation
with the optimal settings of V–V interval in the individual
patient
Evaluation of QuickOpt itself was announced in 2010—
FREEDOM [14] study. Results were not published yet. Avail-
able data are limited to the abstract [22] published at HRS—
with no statistically signiﬁcant change on heart failure
clinical composite score.
Nevertheless, searching for the right method for CRT
optimization has continued. A method, that will be simple,
minimally invasive and has clinical outcome, is needed.5. Limitations
The main limitations are represented by the small size of
sample and subsequent low power of statistical tests and
single center study. This was not a double blind study and
potential bias by the operator cannot be excluded. The three
months follow-up period is probably too short to detect
change in patient's clinical status.6. Conclusion
Using of aortic VTI guided optimization in CRT devices did
not show any proﬁt for non responder patients. Echocardio-
graphy parameters and NYHA status did not change in 3
months of the follow up. Using invasive LVdP/dtmax results in
change of a left ventricular ejection fraction, but NYHA class
remains unchanged.Acknowledgment
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